Bioinformatics platform Massive Bio has partnered with global oncology contract research service NeoGenomics to accelerate the development of cancer treatments.
NeoGenomics will use real-time identification to identify patients that qualify for clinical trials based on their biomarker status. Massive Bio will support NeoGenomics with obtaining patient consent and accelerating the process of further screening and possible enrollment. Through this collaboration, patients who meet the criteria for clinical trials can be identified, allowing patients and healthcare providers to make informed decisions about their potential treatment options.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.